CM-4307
- Generic Name
- CM-4307
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 1130115-44-4
- Unique Ingredient Identifier
- 41XGO0VS1U
- Background
CM-4307 is under investigation in clinical trial NCT03602495 (Donafenib in 131I-Refractory Differentiated Thyroid Cancer).
- Indication
用于治疗既往未接受过全身系统性治疗的不可手术切除或转移性肝细胞癌患者。
- Associated Conditions
- -
- Associated Therapies
- -
HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2022-08-18
- Target Recruit Count
- 93
- Registration Number
- NCT05493332
HAIC Combined With Toripalimab and Donafenib for Advanced BTC
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Lu Wang, MD, PhD
- Target Recruit Count
- 70
- Registration Number
- NCT05350943
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Peking University
- Target Recruit Count
- 156
- Registration Number
- NCT05171166
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2021-12-22
- Target Recruit Count
- 30
- Registration Number
- NCT05166772
Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05161143
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, China
A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2021-11-30
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 10
- Registration Number
- NCT05138159
- Locations
- 🇨🇳
Fudan University, Shanghai, China
Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Anhui Provincial Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05022628
Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2023-06-22
- Target Recruit Count
- 30
- Registration Number
- NCT04962958
- Locations
- 🇨🇳
Lei Zhang, Guangzhou, Guangdong, China
A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors
- First Posted Date
- 2020-07-16
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 30
- Registration Number
- NCT04472858
- Locations
- 🇨🇳
Shanghai Eastern Hospital, Shanghai, Shanghai, China
Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2022-12-01
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 8
- Registration Number
- NCT04402723
- Locations
- 🇨🇳
Institute of Hematology and Blood Disease Hospital, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath